Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06273072 · ClinicalTrials.gov registry record · Phase 2

Metformin IN Asthma for Overweight and Obese Individuals (MINA)

A Phase 2 study of Asthma and Overweight and Obesity, sponsored by Johns Hopkins University.

Recruiting
Registry status
Phase 2
Development phase
100
Enrollment target
2
Study locations

NCT06273072 is a Phase 2 study of Asthma and Overweight and Obesity that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 100 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06273072, a Phase 2 study of Asthma and Overweight and Obesity, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
Phase 2
Development phase
100 participants
Enrollment target
2
Study locations

Study Summary

This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy.

Interventions

  • DRUG Metformin hydrochloride extended-release tablets
  • DRUG Visually identical placebo Metformin hydrochloride extended-release tablets

Study Locations (2)

Maryland

  • Johns Hopkins University - Baltimore

Texas

  • Baylor College of Medicine - Houston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-12-09
Est. Completion 2028-12-31
Phase Phase 2

Sponsor

Johns Hopkins University

1,448 total trials

What the Registry Record Tells You About NCT06273072

The ClinicalTrials.gov registry entry for NCT06273072 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (94% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Metformin hydrochloride extended-release tablets is the first listed.

NCT06273072 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Texas.

Frequently Asked Questions

What is clinical trial NCT06273072 about?

NCT06273072 is a clinical study titled "Metformin IN Asthma for Overweight and Obese Individuals (MINA)". This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy.

What is the current status of trial NCT06273072?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2024-12-09. Estimated completion is 2028-12-31.

What conditions does trial NCT06273072 study?

This clinical trial studies the following conditions: Asthma, Overweight and Obesity, Asthma Chronic.

What interventions are being tested in trial NCT06273072?

The interventions under investigation include: Metformin hydrochloride extended-release tablets (DRUG), Visually identical placebo Metformin hydrochloride extended-release tablets (DRUG).

Who is sponsoring clinical trial NCT06273072?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06273072 being conducted?

This trial has 2 study locations across Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.